DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

BACKGROUND: DD3(PCA3) is the most prostate cancer-specific gene described to date. To assess the clinical utility of DD3(PCA3) a time-resolved fluorescence-based, quantitative RT-PCR analysis for DD3(PCA3) was developed. METHODS: The diagnostic potential of DD3(PCA3) was determined by quantitative measurement of DD3(PCA3) transcripts in non-malignant and malignant prostate specimens. Moreover, DD3(PCA3) transcripts were determined quantitatively in urine sediments obtained after prostatic massage. A cohort of 108 men, admitted for prostate biopsies based on a PSA of >3ng/ml, was studied. RESULTS: Prostate tumors showed a 66-fold up-regulation of DD3(PCA3) (median 158.4.10(5) copies/microg tissue RNA) when compared to benign prostate tissue (median 2.4.10(5) copies/microg tissue RNA). This up-regulation was found in more than 95% of prostate cancer specimens studied. These data revealed that specimens with less than 10% of cancer cells could be accurately discriminated from non-cancer tissues. Hence, detection of a small fraction of prostate cancer cells in a background of normal cells seemed feasible. Therefore, this DD3(PCA3)-based RT-PCR assay was used for the identification of prostate cancer in urine sediments obtained after prostatic massage. From 108 men with a serum PSA value >3ng/ml, 24 men were shown to have prostate cancer upon biopsy. Of these 24 men, 16 were shown to be positive for DD3(PCA3), indicating a sensitivity of the assay of 67%. Furthermore, a negative predictive value of 90% was calculated. CONCLUSION: The quantitative RT-PCR assay for DD3(PCA3) described, bears great promise as a tool for molecular urine analysis. It has great potential in reducing the number of unnecessary biopsies. A multi-center study using this DD3(PCA3) assay can provide the basis for the utility of molecular diagnostics in clinical urological practice.

[1]  R. Naz,et al.  A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis. , 2003, Cancer research.

[2]  Mesut Remzi,et al.  Repeat prostate biopsy: who, how and when?. a review. , 2002, European urology.

[3]  P. Walsh,et al.  Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. , 1993, The Journal of urology.

[4]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[5]  T. Barrette,et al.  α-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation , 2002 .

[6]  J. Moul,et al.  Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. , 1990, The Journal of urology.

[7]  H. Lilja,et al.  Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA. , 1999, Clinical chemistry.

[8]  C. Auffray,et al.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. , 2005, European journal of biochemistry.

[9]  J. Clements,et al.  Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. , 1999, The Journal of urology.

[10]  M. Loda,et al.  Molecular Cloning and Characterization of STAMP1, a Highly Prostate-specific Six Transmembrane Protein that Is Overexpressed in Prostate Cancer* , 2002, The Journal of Biological Chemistry.

[11]  M. Shapero,et al.  Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. , 2001, Cancer research.

[12]  K. Miller,et al.  DNA-based detection of prostate cancer in urine after prostatic massage. , 2001, Urology.

[13]  T. Stamey,et al.  An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. , 1993, The Journal of urology.

[14]  C. Young,et al.  The expression of a variant prostate-specific antigen in human prostate. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  A. Partin,et al.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.

[16]  L. Hood,et al.  Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[18]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[19]  D McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[20]  F. Bosman,et al.  The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. , 2001, The Journal of urology.

[21]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[22]  M. Augustus,et al.  Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. , 2000, The Journal of urology.

[23]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[24]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[25]  T. Libermann,et al.  PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.

[26]  M. Augustus,et al.  PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[28]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[29]  H. Lilja,et al.  Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes. , 2001, BioTechniques.

[30]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[31]  Dale McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[32]  H. Klocker,et al.  Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen , 1996, Cancer.